St950000119

PUBLIC NOTICE COPY

February 6, 1995



CERTIFIED MAIL
RETURN RECEIPT REQUESTED
P 253 155 587

95 FEB 13 13 6:03

OPPT Document Processing Center (7407)
ATTN: Section 8(e) Coordinator
Office of Pollution Prevention and Toxics (OPPT)
US Environmental Protection Agency
Washington, DC 20460

RE:

TSCA Section 8(e) Notice

COMPANY SANITIZED

Dear Sir or Madam:

This notice is being submitted by Rhône-Poulenc Ag Company (RPAC) to the Environmental Protection Agency (EPA) in accordance with the provisions of Section 8(e) of the Toxic Substances Control Act (TSCA), 15 USC § 2607 (e).

We are submitting the results of toxicity studies on


. Only limited quantities of purposes.

this compound have been synthesized for research and development purposes.

RPAC claims the alpha-numeric designation and the specific chemical identity of the substance at issue to be confidential business information (CBI). The chemical substance may be nonconfidentially identified as a "heterocycle".

In a Chernoff-Kavlock assay, pregnant CD-1 mice (20 females/group) were dosed by gavage on gestation days 6 through 13, inclusive. Mice were allowed to litter naturally, and pup viability and growth was observed on postnatal days 1 through 4. For at 100 mg/kg/day, 17 of 20 females died during the study. One additional female had complete litter resorption, and the two remaining females had viable litters. No evidence of toxicity was noted in the pups from these litters. AT 25 mg/kg/day, no maternal toxicity was observed, but a statistically significant decrease in the mean number of viable male pups per litter was noted on postnatal days 1 and 4 (5.6 compared to a control of 7.4 on postnatal day 1 and 5.4 compared to a control of 7.1 on postnatal day 4). However, no effects were noted on the mean number of female pups per litter or on the mean number of pups per litter for males and females combined. Percent prenatal loss at 25 mg/kg/day was statistically higher than control of 9.3%). Pup weight for females was statistically lower than control on postnatal day 1, but weights for both male and female pups were statistically higher than control on postnatal day 4.

In a subchronic toxicity study, test material was administered to male CD-1 mice via admixture in the diet at levels of 30 or 100 ppm (10 mice/group) for 8 weeks. Mortality was 20% at 30



ppm and 100% at 100 ppm. Clinical signs of reduced motor activity, irritability to touch, piloerection, and hunched posture were observed at both 30 and 100 ppm. Necropsy of animals that died during the study revealed red fluid, possibly blood, in abdominal and thoracic cavities of some of the animals at 100 ppm. Extramedullary hemopoiesis in the spleen and centrilobular and hemorrhagic necrosis in the liver were observed in a few animals at 100 ppm. Animals at 30 ppm surviving to study termination exhibited changes in the liver consisting of periportal fatty change and centrilobular hypertrophy.

## SUPPORT INFORMATION OF CONFIDENTIALITY CLAIMS

- 1. Claims of confidentiality are being made on behalf of RPAC.
- 2. RPAC asserts this claim of confidentiality until such time as a specific chemical is approved for use in the United States. In the event that the chemical is never approved, RPAC asserts that the CBI information should be provided permanent protection. The structure and use of the chemical are unique. Disclosure of this information would provide our competitors with information on facets of our business that would be detrimental to our competitive position.
- 3. The information claimed as confidential has not been previously disclosed to any other governmental agency or to EPA.
- 4. This information has been disclosed to only a very limited number of investigators outside of RPAC who have performed either toxicity or efficacy testing. These individuals operate under a strict secrecy agreement. Any individuals who may work with the chemical will have all health/toxicology information disclosed to them as well, but only on the basis of strict secrecy and respect for the CBI nature of the information.
- 5. Any individuals to whom the CBI is revealed are warned of the nature of the information. Further, they are informed of their obligations to maintain secrecy should they terminate their employment with RPAC.
- 6. None of the information claimed as confidential appears in or is referred to in any advertising or promotional materials for the chemical or the end product containing it, professional or trade publications, or any other media available to the public or to our competitors. Appropriate warnings do appear on safety data sheets, as RPAC considers that individuals who are requested to work with the chemicals have every right to know as much about the chemicals' toxicity as possible. Further, the information is only considered to be CBI with respect to the general public, insofar as our competitors could use the information in an unfairly competitive nature.
- 7. No previous confidentiality determinations have been made by EPA, other Federal agencies or courts in connection with this information.
- 8. RPAC believes that disclosure of this information to the general public would be likely to result in substantial harm to its competitive position. Disclosure of the alpha numeric designation and chemical name would provide some competitors with information about the specific chemistry of this area of our research and our business. Further, the type of toxicological testing being reported in the TSCA 8(e) notice would provide competitive information about this chemical's status in the research and development process and, therefore, the time remaining until commercialization.
- 9. A patent has not been issued for the specific chemical structure. However, the generic chemical structure is covered by a patent that is currently pending.

## PUBLIC NOTICE COPY

- 10. The chemical is not available commercially. It is in the earliest stages of research and development for pesticide use and is unlikely to be developed into a commercial product.
- 11. We believe that disclosure of the chemical name would allow a competitor to synthesize this chemical. RPAC has invested a large amount of time and money into research of this particular chemical family, and information on specific chemical structures would harm our competitive position.
- 12. Disclosure of the chemical structure might reveal information on processes used to synthesize this compound.
- 13. CAS number has not yet been assigned.
- 14. Currently, the chemical is not the subject of FIFRA regulation or reporting.

Further questions regarding this submission may be directed to the undersigned at 919-549-2222.

Sincerely,

Glenn S. Simon, PhD, DABT

Director of Toxicology



## UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

Glenn S. Simon, Ph.D., DABT Director of Toxicology Rhône-Poulenc P.O. Box 12014 2 T.W. Alexander Drive Research Triangle Park, North Carolina 27709

OFFICE OF PREVENTION, PESTICIDES AND **TOXIC SUBSTANCES** 

APR 1 8 1995

EPA acknowledges the receipt of information submitted by your ofganization under Section (e) of the Toxic Substances Control Act (TSCA). For your re erence, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests" .

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

> Document Processing Center (7407) Attn: TSCA Section 8(e) Coordinator Office of Pollution Prevention and Toxics U.S. Environmental Protection Agency Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan Risk Analysis Branch

13330A

Enclosure

Recycled/Recyclable Printed with Soy/Canola lnk on paper that contains at least 50% recycled fiber

## Triage of 8(e) Submissions

Date sent to triage:	APR 1	9 1995	NON	-CAP	CAP	
Submission number: _	13332	DA	TSCA	A Inventory:	Υ Ν	
Study type (circle appr	ropriate):					
Group 1 - Dick Cleme	nts (1 copy tota	1)				
ECO	AQUATO					
Group 2 - Ernie Falke	(1 copy total)					
ATOX	SBTOX	SEN	w/NEUR			
Group 3 - Elizabeth M	largosches (1 co	opy each)				
(stex	стох	EPI	RTOX	GTOX		
STDX/ONCO	CTOX/ONCO	IMMUNO	CYTO	NEUR		
Other (FATE, EXPO, M	MET, etc.):					
Notes:				TED TDIAGE	DATADAC	E ENTDV
THIS IS THE ORIGI	NAL 8(e) SUBM	ISSION; PLI	EASE REFILE AF	IEH IHIAGE	DATABASI	EENIRT
		For Contra	ctor Use Only			
entire docume	1: 1 2	pages _	7,3	pages	1,2,3	<del></del>
Notes:	~	A0 /		.1	1	
Contractor revi	ewer:		Date:	4/3	195	

_
5
Ī,
<b>&gt;</b>
×
7
ı
Ţ
₹.
₫.
Q
Z
_
Z
ACK
₹CKI
TRACK
SE TRACKING DBASE
AGE TRACK
RIAGE TRACKI
TRIAGE TRACKI
INTRIAGE TRACK
ATS/TRIAGE TRACKI
SCATS/TRIAGE TRACKI
CECATS/TRIAGE TRACKI

NDE RWAY ORKI KODII KA I S CHANGI S IUED ORTINUED	P F C 01 02 04 01 02 04	e ent of
WOLUNTARY ACTIONS:  AMO ACTION RI PORTIT D  AMO STUDIES PLANNI DAINDI RWAY  BAGS NOTIFICATION OF WORKE ROTH RY  BAGS NOTIFICATION OF WORKE RY OFF RA  BAGS PROCESSALANDI ING CHANGES  BAGS APPAUSE DISCONTINUED  BAGS CONFIDENTIAL	INFORMATION TYPE:  024 IMMUNO (AUMAN) 024 CLASTO (IN VITRO) 024 CLASTO (IN VITRO) 024 CLASTO (AUMAN) 024 CLASTO (HUMAN) 025 CLASTO (HUMAN) 026 CLASTO (HUMAN) 027 CLASTO (HUMAN)	RiD posticide
	1NFOR 0243 0245 0245 0246 0251 0251	and the second
LWP DATE  ACTIONS)  RETING RATIONALF  REENING  CASE  CONFIGER  CONFIGER	01 62 64 01 62 64	Jonath Jonath
S S S	EPICLIN  HUMAN EXPOS (PROD CONTAM)  HUMAN EXPOS (ACCIDENTAL)  HUMAN EXPOS (ACCIDENTAL)  HUMAN EXPOS (MONITORING)  HUMAN EXPOS (MONITORING)  HUMAN EXPOS (MONITORING)  HOWAN EXPOS (MONITORING)  HOWAN  ENCORAGE FATE  HOWAN  RESPONSE REGEST DELAY  PRODICOMPICHEM ID  ONFIDENTIAL  ALLERG (HUMAN)  METABPHARMACO (HUMAN)  METABPHARMACO (HUMAN)  ON 22 M  METABPHARMACO (HUMAN)	MATED HIGH  WED AND HIGH  BESMANN
INFORMATION REQUESTED 6501 NO INFO REQUESTED (TE 0502 INFO REQUESTED (VC 0504 INFO REQUESTED (REDISPOSITION:  (C.S.) REFER TO CHEMICAL  (C.S.) CSRAD DATE:	EPICLIN HUMAN EXPOS (PROD CC HUMAN EXPOS (ACCIDEN HUMAN EXPOS (ACCIDEN HUMAN EXPOS (MONITY) ECO/AQUA TOX ENV. OCCCRELFATE EMER INCI OF ENV CONT RESPONSE REQEST DELA PROD/COMP/CHEM ID REPORTING RATIONALE CONFIDENTIAL ALLERG (HUMAN) ALLERG (ANIMAL) METAB/PHARMACO (ANI METAB/PHARMACO (HUI	gill sp
	11 02 04 0216 11 02 04 0217 11 02 04 0217 11 02 04 0219 11 02 04 0220 11 02 04 0222 11 02 04 0222 11 02 04 0226 11 02 04 0229 11 02 04 0229 11 02 04 0229 11 02 04 0229 11 02 04 0229	YES (DROP/REFER) NO (CONTINUE) REFER LO LECTION CORT
Sou(enc	F C C C C C C C C C C C C C C C C C C C	YES (DE NO (CO REFF.R
10. 0395-1333 HIWF AB COM 02/04/95 OCYCLE	INFORMATION TYPE:  0201 ONCO (HUMAN) 0202 ONCO (ANIMAL) 0203 CELL TRANS (IN VITRO) 0204 MUTA (IN VITRO) 0205 MUTA (IN VITRO) 0206 MUTA (IN VITRO) 0206 MUTA (IN VITRO) 0206 MUTA (IN VITRO) 0207 REPRO/TERATO (HUMAN) 0209 NEURO (HUMAN) 0210 ACUTE TOX. (HUMAN) 0211 CHR TOX. (HUMAN) 0212 ACUTE TOX. (HUMAN) 0213 SUB ACUTE TOX. (ANIMAL) 0214 SUB ACUTE TOX. (ANIMAL) 0215 CHRONIC TOX (ANIMAL) 0215 CHRONIC TOX (ANIMAL) 0215 CHRONIC TOX (ANIMAL)	
CECATS DATA. Submission # 8EE TYPE INT. BUPI SUBMITTER NA SUBMITTER NA CHEMICAL NA CHEMICAL NA	0201 0203 0203 0203 0204 0205 0206 0211 0211 0211 0211 0211	CAS SR

